Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024

19 Dec 2024 07:00 CET

Oslo, 19 December 2024: Reference is made to the stock exchange notice published
by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the contemplated
business combination between the Company and Zelluna Immunotherapy AS and the
fully committed private placement.

The Company's board of directors (the "Board") hereby calls for an extraordinary
general meeting on 9 January 2025 at 09:00 CET (the "EGM") to resolve upon the
matters proposed by the Board in the attached EGM notice.

The EGM will be held electronically. For participation, please log in at
https://dnb.lumiagm.com/ with the user ID and password provided.

All documents and appendices regarding the EGM are made available at the
Company's website: www.ultimovacs.com (https://www.ultimovacs.com).

For further information, please see www.ultimovacs.com
(https://www.ultimovacs.com) or contact:

Hans Vassgård Eid, Interim CEO and CFO, Ultimovacs ASA
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632

More information:
Access the news on Oslo Bors NewsWeb site

635141_Appendix 5 - Pre-committing investors in the Private Placement.pdf
635141_Appendix 1 - Registration and proxy form to the Extraordinary General Meeting.pdf
635141_Appendix 4 - Biographies for proposed Board.pdf
635141_Appendix 3 - Draft Articles of Association.pdf
635141_Appendix 2 - List of shareholders in Zelluna.pdf